GlassScriptPhysician profile
Arrvind Raghunath
NPI 1952753139
$1,619.38
in general payments reported to CMS, 2019-2025
26 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $318 · 2023: $297 · 2024: $566 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $260.77 | 2022-2023 | Ultomiris |
| Steris Corporation | $153.17 | 2024 | |
| Incyte Corporation | $147.86 | 2022-2024 | Jakafi, Monjuvi, Pemazyre |
| Sumitomo Pharma America, INC. | $126.94 | 2023 | Orgovyx |
| Galvanize Therapeutics, INC | $116.52 | 2024 | Aliya System |
| Novartis Pharmaceuticals Corporation | $115.24 | 2024-2025 | |
| Eisai INC. | $106.40 | 2025 | |
| Pfizer INC. | $71.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.58 | 2023-2024 | Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $59.95 | 2024-2025 | Alunbrig, Ninlaro |
| Genentech USA, INC. | $59.24 | 2023-2025 | Venclexta, Phesgo |
| Tempus Ai, INC | $48.13 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $31.10 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $25.61 | 2024 | |
| Daiichi Sankyo INC. | $24.59 | 2025 | Datroway |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.64 | 2025 | Ojjaara |
| Genmab U.S., INC. | $23.58 | 2023 | Epkinly |
| Celgene Corporation | $23.40 | 2023 | Pomalyst |
| Caris Mpi, INC. | $22.94 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $22.01 | 2024 | Brukinsa |
| Array Biopharma INC | $17.24 | 2025 | Mektovi, Lorbrena, Braftovi |
| Azurity Pharmaceuticals, INC. | $16.82 | 2025 | Danziten |
| Seagen INC. | $16.77 | 2023 | Tukysa |
| Karyopharm Therapeutics INC. | $16.03 | 2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $14.74 | 2024 | Imfinzi |
| Jazz Pharmaceuticals INC. | $13.93 | 2023 | Zepzelca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arrvind Raghunath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.